BioMarin Soars 18% After Folding In The $4.8 Billion Takeover Of Amicus

BioMarin Pharmaceutical (BMRN) said Friday it will acquire Amicus Therapeutics (FOLD) for $4.8 billion in a deal that adds two rare disease drugs to its portfolio. On the stock market today, Amicus stock catapulted 30.2% to 14.18, just under the takeover price of $14.50 per share. The biotech stock is highly rated and has climbed roughly 94% over the past…